the board and from the company. John C. Lechleiter, Ph.D., currently
president and chief operating officer, will assume the role of chief
executive officer as of April 1, 2008.
-- In January 2008, the FDA approved Cialis for once-daily use to treat
-- In December, the company entered into a licensing and development
agreement with BioMS Medical Corp., granting Lilly exclusive worldwide
rights to BioMS Medical's lead multiple sclerosis (MS) compound,
MBP8298. The compound is currently being evaluated in two pivotal
phase III clinical trials in secondary progressive MS (SPMS) and one
Phase II clinical trial in relapsing-remitting MS (RRMS). The
transaction closed in January, 2008.
-- In December, the company ceased production at its manufacturing
facility in Basingstoke, England as part of the previously-announced
-- In November, the FDA approved Cymbalta for the maintenance treatment
of major depressive disorder (MDD) in adults.
-- In October, the company acquired the rights to a portfolio of
transient receptor potential vanilloid sub-family 1 (TRPV1) antagonist
molecules from Glenmark Pharmaceuticals S.A. The lead compound, GRC
6211, is currently in Phase II development as a potential next-
generation treatment for various pain conditions, including
"Lilly completed a very successful year by continuing to deliver strong
financial results to our shareholders in the fourth quarter," commented
Sidney Taurel, chairman and chief executive officer. "Our additional
investment in sales and marketing helped fuel accelerated double-digit
sales growth this quarter, which was once again driven mainly by volume.
Our performance provided the financial flexibility we sought to make
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved